Large gap with delayed quotes
|
Last quote
12/27/2024 -
16:30:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
712.40
-4.28
(
-0.60% )
|
712.57
|
500 |
713.23
|
200 |
Analysis date: 24.12.2024
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 24.12.2024.
Interest
Weak
Weak
Weak interest since 24.12.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 24.12.2024 at a price of 714.47.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, at its current price the stock is fairly valued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 24.09.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-5.56%
-5.56%
The four week relative underperformance versus SP500 is 5.56%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 25.10.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.20%.
Mkt Cap in $bn
78.59
78.59
With a market capitalization >$8bn, REGENERON PHARMA is considered a large-cap stock.
G/PE Ratio
0.82
0.82
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
13.19
13.19
The estimated PE is for the year 2027.
LT Growth
10.87%
10.87%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
19
19
Over the last seven weeks, an average of 19 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
84
84
For 1% of index variation, the stock varies on average by 0.84%.
Correlation
0.42
0.42
42.30% of stock movements are explained by index variations.
Value at Risk
85.81
85.81
The value at risk is estimated at USD 85.81. The risk is therefore 12.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.04.2004
02.04.2004